TeraRecon adds prostate cancer detection to its Eureka AI platform

Bot Image secured clearance for the prostate cancer software, ProstatID, from the U.S. Food and Drug Administration (FDA) in July of last year for use with biparametric MRI. The software has been shown to help increase the detection of the disease while also decreasing false positives, TeraRecon said.

Go to publisher site for the complete article:

Read More

No items found.